8-KRegulation FDOther EventsExhibits & Filings

ALTRIA GROUP, INC. 8-K Report, Regulation FD Disclosure (Oct 20, 2022)

Filed October 20, 2022For Securities:MO

Summary

Altria Group, Inc. (MO) announced a significant strategic development regarding its U.S. commercialization rights for the IQOS Tobacco Heating System®. On October 19, 2022, a subsidiary of Altria entered into a purchase agreement with a subsidiary of Philip Morris International Inc. (PMI) that will result in Altria assigning exclusive U.S. commercialization rights for IQOS to PMI, effective April 30, 2024. This transaction is structured with substantial financial consideration for Altria. The company received $1.0 billion upfront upon signing the agreement and is set to receive an additional $1.7 billion plus interest by July 15, 2023, totaling approximately $2.7 billion in cash. This move marks a material shift in Altria's involvement with the IQOS product in the U.S. market.

Key Highlights

  • 1Altria to assign exclusive U.S. commercialization rights for IQOS to PMI, effective April 30, 2024.
  • 2Total cash consideration for Altria amounts to approximately $2.7 billion.
  • 3Altria received $1.0 billion upfront on October 19, 2022.
  • 4An additional $1.7 billion payment is due to Altria by July 15, 2023, with interest.
  • 5The agreement concludes Altria's U.S. commercialization relationship with PMI for IQOS.
  • 6The filing includes forward-looking statements subject to risks and uncertainties.

Frequently Asked Questions

Altria will receive approximately $2.7 billion in total cash consideration. This includes $1.0 billion received upfront and an additional $1.7 billion plus interest expected by July 15, 2023.

Altria will assign exclusive U.S. commercialization rights to PMI effective April 30, 2024.

The 8-K filing states the agreement is to 'transition and ultimately conclude the relationship between Altria and PMI with respect to the IQOS System in the U.S.' The specific strategic reasons beyond this are not detailed in this filing, but it represents a significant shift in Altria's product strategy.

Yes, the filing notes that the transaction is subject to risks and uncertainties, including Altria's ability to realize the expected benefits and the outcome of any potential legal proceedings or investigations related to the transaction.